Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 620 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Non-malignant Pain
Interventions
Buprenorphine transdermal patch, Placebo to match BTDS
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
21
States / cities
Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 17 more
Completed Phase 3 Interventional Results available

Buprenorphine Group Medical Visits in Primary Care

NCT02526212
Conditions
Opioid-Related Disorders
Interventions
G-BMT, Treatment as usual, Buprenorphine
Behavioral · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Opioid Dependence
Interventions
BEMA Buprenorphine NX, Buprenorphine
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Orem, Utah • Salt Lake City, Utah
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Multimodal Fetal and Placental Imaging and Biomarkers of Clinical Outcomes in Opioid Use Disorder

NCT06415994
Conditions
Opioid Use Disorder, Substance-Related Disorders, Pregnancy Related, Narcotic-Related Disorders, Buprenorphine Dependence, Methadone Dependence
Interventions
Buprenorphine or Methadone Treatment, Fetal and Placental MRI, Child Developmental Assessment, Questionnaires, Blood and Placental Samples
Drug · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Senthil Sadhasivam
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Results available

Long-term Open-Label Safety Study to Evaluate EN3409

NCT01755546
Conditions
Low Back Pain, Osteoarthritis, Neuropathic Pain
Interventions
EN3409
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Opioid Use Disorder
Interventions
Talk About It (conversation aid)
Behavioral
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Springfield, Massachusetts
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
New York, New York
Conditions
Opioid Use Disorder
Interventions
Psilocybin with facilitated counseling
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement

NCT05897788
Conditions
Opioid Use Disorder, Opioid Dependence With Current Use (Disorder)
Interventions
Text Message Check-ins, Contingency Management
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,808 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
Interventions
BNI Chatbot, OUD Education & Treatment Resources
Behavioral
Lead sponsor
Center for Progressive Recovery, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Results available

Prolonged Exposure Therapy for PTSD and Opioid Use Disorder

NCT04104022
Conditions
Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions
Prolonged Exposure Therapy, Attendance-based monetary incentives
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Pain
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 1 more
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Conditions
Opioid Use Disorder
Interventions
Psychosocial treatment
Behavioral
Lead sponsor
Philadelphia College of Osteopathic Medicine
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Atlantic City, New Jersey • Philadelphia, Pennsylvania
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Accepts healthy volunteers

Youth Opioid Recovery Support: Improving Care Systems

NCT04015115
Conditions
Opioid-Related Disorders
Interventions
Youth Opioid Recovery Support service model
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 26 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Depression, Major Depressive Disorder
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Jordan F. Karp
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Substance-Related Disorders
Interventions
RDC-0313 + Buprenorphine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Francisco, California
Completed Not applicable Interventional Accepts healthy volunteers

Opioid Dependence Treatment Therapies in Pregnancy

NCT03098407
Conditions
Opioid-Related Disorders, Pregnancy
Interventions
Buprenorphine, Methadone
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Opioid Use Disorder
Interventions
Semaglutide, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine for Prisoners

NCT00574067
Conditions
Heroin Addiction
Interventions
Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP, Counseling +CHC
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Jessup, Maryland